ArticleDermatology and therapy2026
Efficacy and Tolerability of 0.2% Thiamidol Cream for Facial Hyperpigmentation: A Randomized, Double-Blind, and Vehicle-Controlled Study.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03926845 (Efficacy and Tolerability of an Isobutylamido-thiazolyl-resorcinol Cream 0.2% for Facial Hyperpigmentation, A Randomized Double-blind and Vehicle-Controlled Study), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Tolerability of an Isobutylamido-thiazolyl-resorcinol Cream 0.2% for Facial Hyperpigmentation, A Randomized Double-blind and Vehicle-Controlled Study
Who cites it
1 citing paper in PubMed.
- Beyond Tint: Active Ingredient Strategies for Post-Inflammatory Hyperpigmentation due to Visible Light in Skin of Color.Photodermatology, photoimmunology & photomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFacial hyperpigmentation is a condition that often shows limited response to treatment. Thiamidol is a proven human tyrosinase (hTyr) inhibitor. However, evidence from randomized controlled trials evaluating the effectiveness of Thiamidol in reducing facial hyperpigmentation remains limited.
methodsThis study is the first and largest randomized, double-blind, vehicle-controlled trial to evaluate the effectiveness of 0.2% Thiamidol cream in the treatment of facial hyperpigmentation in both sexes. A total of 200 participants with facial hyperpigmentation were randomized to either a Thiamidol cream or a vehicle cream group for 12 weeks. Blinded physicians assessed participants' scores on the modified Melasma Area and Severity Index (mMASI) using standardized photographs, with physician and patient global assessments and digital color analysis performed at weeks 4, 8, and 12.
resultsOf the 200 participants enrolled, 196 completed the study. The Thiamidol group showed significantly greater reductions in their mMASI scores (indicating improvement) than the vehicle group at all time points: the reduction from baseline were 11.8% vs 5.4% at week 4, 27.9% vs 13.6% at week 8, and 36.1% vs 16.1% at week 12 (all P < 0.001). The physician global assessments indicated slight to moderate improvement at weeks 8 and 12 (P < 0.001 and P = 0.001, respectively). The patient global assessments and digital color analysis showed no significant differences between groups. We found no statistically significant differences between the groups in the improvement of freckles or solar lentigines. No significant adverse events were reported in either group.
conclusionWe found Thiamidol to be effective, well tolerated, and suitable for both sexes in the treatment of facial hyperpigmentation. These findings support its potential for broader clinical application in cosmetic dermatology.
trial registrationClinicalTrials.gov (NCT03926845).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.